MedKoo Cat#: 526765 | Name: SB-674042

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB-674042 is potent and selective OX1R antagonist. SB-674042 binds with high affinity to OX1R and mediates intracellular calcium flux in OX1R-expressing cells.

Chemical Structure

SB-674042
SB-674042
CAS#483313-22-0

Theoretical Analysis

MedKoo Cat#: 526765

Name: SB-674042

CAS#: 483313-22-0

Chemical Formula: C24H21FN4O2S

Exact Mass: 448.1369

Molecular Weight: 448.52

Elemental Analysis: C, 64.27; H, 4.72; F, 4.24; N, 12.49; O, 7.13; S, 7.15

Price and Availability

This product was removed for the commercial reasons.
Related CAS #
No Data
Synonym
SB 674042; SB-674042; SB674042.
IUPAC/Chemical Name
(S)-(5-(2-fluorophenyl)-2-methylthiazol-4-yl)(2-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)pyrrolidin-1-yl)methanone
InChi Key
HYBZWVLPALMACV-KRWDZBQOSA-N
InChi Code
InChI=1S/C24H21FN4O2S/c1-15-26-21(22(32-15)18-11-5-6-12-19(18)25)24(30)29-13-7-10-17(29)14-20-27-28-23(31-20)16-8-3-2-4-9-16/h2-6,8-9,11-12,17H,7,10,13-14H2,1H3/t17-/m0/s1
SMILES Code
O=C(N1[C@H](CC2=NN=C(C3=CC=CC=C3)O2)CCC1)C4=C(C5=CC=CC=C5F)SC(C)=N4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 448.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat Struct Mol Biol. 2016 Apr;23(4):293-9. doi: 10.1038/nsmb.3183. Epub 2016 Mar 7. PubMed PMID: 26950369. 2: Jeon Y, Park KB, Pervin R, Kim TW, Youn DH. Orexin-A modulates excitatory synaptic transmission and neuronal excitability in the spinal cord substantia gelatinosa. Neurosci Lett. 2015 Sep 14;604:128-33. doi: 10.1016/j.neulet.2015.08.001. Epub 2015 Aug 4. PubMed PMID: 26254164. 3: Heifetz A, Morris GB, Biggin PC, Barker O, Fryatt T, Bentley J, Hallett D, Manikowski D, Pal S, Reifegerste R, Slack M, Law R. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis. Biochemistry. 2012 Apr 17;51(15):3178-97. doi: 10.1021/bi300136h. Epub 2012 Apr 5. PubMed PMID: 22448975. 4: Ward RJ, Pediani JD, Milligan G. Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging. Br J Pharmacol. 2011 Mar;162(6):1439-52. doi: 10.1111/j.1476-5381.2010.01156.x. PubMed PMID: 21175569; PubMed Central PMCID: PMC3058174. 5: Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmet hyl-acetamide (EMPA). Mol Pharmacol. 2010 Jul;78(1):81-93. doi: 10.1124/mol.110.064584. Epub 2010 Apr 19. PubMed PMID: 20404073. 6: Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol. 2009 Sep;76(3):618-31. doi: 10.1124/mol.109.055152. Epub 2009 Jun 19. PubMed PMID: 19542319. 7: Ellis J, Pediani JD, Canals M, Milasta S, Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem. 2006 Dec 15;281(50):38812-24. Epub 2006 Oct 2. PubMed PMID: 17015451. 8: Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6. Epub 2003 Dec 22. PubMed PMID: 14691055; PubMed Central PMCID: PMC1574197.